Nevirapine + Daclatasvir = Precautionary

Effect on Concentration

Nevirapine
No change
Applies within class?
No
Daclatasvir
Decrease
Applies within class?
No

Pharmacologic Effects

Nevirapine
Effect
N/A
Applies within class?
No
Daclatasvir
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 13-Jul-2018

Summary

Per the manufacturer, coadministration of nevirapine or efavirenz with daclatasvir is predicted to reduce daclatasvir exposure due to CYP3A4 induction. Because of the lack of solid data, use of these agents concomitantly is not recommended.

Sources

Daclatasvir plasma concentration assessment in HIV–HCV-coinfected real-life patients ^

Study Design

A review of various drug interactions (both studied and theoretical) and description of their clinical management

Study Results

Several interactions have not been formally studied, but inferences are made based upon what is known of each drug's pharmacokinetic or pharmacodynamic properties.

Study Conclusions

Daclatasvir is a substrate of CYP3A, and as such inhibitors or inducers may alter drug concentrations and various clinical approaches may manage these interactions.

References

Taton A, Colson, P, Dhiver C, Ruiz JM, Bregigeon S, Tomei C, Lacarelle B. Daclatasvir plasma concentration assessment in hiv–hcv-coinfected real-life patients. Antiviral Therapy. 2017; : 731-733.